Expression of the Androgen Receptor and its Correlation with Molecular Subtypes in 980 Chinese Breast Cancer Patients

Ji-ping Qi1, You-lin Yang2, Hong Zhu1, Jianmin Wang3, Ying Jia1, Na Liu1, Yue-jia Song1, Li-kun Zan1, Xu Zhang1, Min Zhou1, Yun-he Gu1, Tao Liu1, David G. Hicks3 and Ping Tang3

1Department of Pathology, First Clinical Hospital, Harbin Medical University, Harbin 150001, PR China. 2Department of Digestive Systems, First Clinical Hospital, Harbin Medical University, Harbin 150001, PR China. 3Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA. 4RTI Health Solution, Research Triangle Park, NC. Corresponding author email: yl_y123456@163.com; ping_tang@urmc.rochester.edu

Abstract

Background: Recent studies have shown that androgen displays an inhibitory effect on breast cancer cell lines that express androgen receptor (AR) but not estrogen receptor (ER) and progesterone receptor (PR). We have previously reported that approximately 1/3 of ER negative high grade invasive ductal carcinomas express AR. Thus, AR can serve as a potential therapeutic target for this group of patients.

Aim: Here we investigated AR expression patterns in 980 consecutive breast carcinomas.

Results: We found that (1) AR was expressed more frequently (77%) than ER (61%) and PR (60%) in breast carcinomas; (2) AR expression was associated with ER and PR expression ($P$, 0.0001), small tumor size ($P$, 0.0324) and lower Ki-67 expression ($P$, 0.0013); (3) AR expression was found in 65% of ER negative tumors; (4) AR expression was associated with PR and Ki-67 in ER negative tumors, but not in ER positive tumors; (5) AR expression was higher in ER positive subtypes (Luminal A, Luminal B and Luminal HER2 subtypes, 80%–86%) and lower in ER negative subtypes [HER2, triple negative (TN), and TN EGFRe positive subtypes; 52%–66%], with over 50% of TN tumors expressing AR.

Conclusion: More breast carcinomas express AR than ER and PR, including significant numbers of ER negative and TN tumors, for which AR could serve as a potential therapeutic target.

Keywords: androgen receptor, breast cancer, estrogen receptor, HER2, Ki-67, molecular classification, progesterone receptor
Introduction
Breast cancer is one of the most common malignancies in women worldwide and the second most common cause of cancer-related death in women. Currently, breast cancer is treated by multi-modality therapies based on the pathologic characteristic of each tumor.1,2 Targeting therapies to estrogen receptor (ER) and HER2 in breast carcinoma have shown remarkable clinical efficacy for the appropriate subsets of patients.3,4 However, only about 15% and 70% of breast cancers are positive for HER2 and ER, respectively; and about 15% of the tumors are ER, progesterone receptor (PR) and HER2 negative [Triple Negative (TN) tumors],5,6 which will not benefit from these targeted therapies.

The role of the androgen receptor (AR) in breast carcinomas has drawn great attention in recent years, especially due to its expression in ER and PR negative breast carcinomas.7,8 We have previously reported that approximately 1/3 of ER negative high grade invasive ductal carcinomas express AR.9 Breast cancer with BRCA1/2 mutants also shows a similar rate of AR expression.10 AR expression also correlates with better prognosis for both primary and metastatic breast cancer.11,12 A recent study has shown that androgen dehydroepiandrosterone sulfate (DHEAS) inhibits the growth of breast cancer cell lines that express AR but not ER and PR.13 Thus, AR has been suggested to be able to serve as a potential therapeutic target for the subgroup of breast carcinomas that are AR positive/ER negative.14

Breast cancer is a very heterogeneous group of tumors that vary in clinical behavior and response to therapy. Gene expression profiling has provided the molecular basis for the heterogeneity of breast cancer; and also subdivided breast cancer into several clinically distinct molecular subtypes.15–17 ER, PR, HER2, and more recently Ki-67, CK5/6 and EGFR have been used by many investigators as immunohistochemical (IHC) surrogates for molecular classification with comparable results.18–22 Although no universally accepted definition for each subtype is present at this point, most studies have chosen to use definitions proposed by Nielsen,18 Livasy19 and Cheang.20 This current study aims to investigate the expression patterns of AR in a large cohort of Chinese breast cancer patients, with a focus on ER negative and TN breast cancer, and breast cancer of different molecular subtypes.

Materials and Methods
Patient selection
A total of 980 consecutive cases of invasive breast carcinomas between 2004 and 2009 were reviewed from the files of the Department of Pathology of the First Clinical Hospital of Harbin Medical University in China. 89 cases of DCIS were also identified from the same period and excluded from the study. All patients underwent surgical excision before receiving chemotherapy, radiotherapy or adjuvant hormonal therapy. Clinicopathological information including age of patients, tumor size and lymph node status were obtained from the files. The histological types and grades of the tumors were determined by following the WHO classification (2003).23

Immunohistochemistry analysis
The study protocol was approved by the Human Ethics Review Committee of Harbin Medical University. The information for primary antibodies for AR, ER, PR, HER2, Ki-67, and EGFR used in the study is listed in Table 1. Formalin-fixed, paraffin-embedded tissue blocks were cut into 3 micron thick serial sections that were mounted on pre-coated slides. The sections were de-paraffinized, rehydrated, and rinsed in distilled water, and then treated with 3% hydrogen peroxide.

Table 1. Sources and dilutions of antibodies.

| Antibody | Poly- vs. monoclonal | Clone no. | Manufacturer          | Dilution          |
|----------|----------------------|-----------|-----------------------|-------------------|
| AR       | monoclonal          | AR441     | Maixin_Bio, China     | Working liquid    |
| ER       | monoclonal          | EP1       | ZSGB-BIO, China       | Working liquid    |
| PR       | monoclonal          | SP2       | Maixin_Bio, China     | Working liquid    |
| Ki-67    | monoclonal          | EP5       | ZSGB-BIO, China       | Working liquid    |
| HER2     | monoclonal          | EP3       | ZSGB-BIO, China       | Working liquid    |
| EGFR     | monoclonal          | EGFR.113  | Maixin_Bio, China     | Working liquid    |
solution for 10 minutes to block endogenous peroxidases. Antigen retrieval was achieved by heating in a water bath with EDTA (pH 9.0; ZLI-9069; 901022, ZSGB-BIO, China) for AR, or in citrate buffer (pH 6.0) for ER, PR, HER2 and Ki67, or pretreated in pepsin (ZLI-9013; 572031A, ZSGB-BIO, China) for EGFR. The aforementioned primary antibodies were incubated for an hour, and then incubated with the secondary, biotinylated antibody for 30 minutes. After washing, sections were incubated with streptavidin-peroxidase for 40 minutes. 3,3′-diaminobenzidine (DAB) was used as chromogen. Samples were scored as positive for ER, PR and AR (Figure 1) when at least 10% of nuclei of tumor cells were immunoreactive. Ki67 expression was determined by mean positive nuclear staining percentage from 10 high power fields; over 14% is considered positive. HER2 was considered positive when 10% of tumor cells with 3+ membranous staining was observed; EGFR was considered positive when tumor cells with 1+ or greater staining were observed.

IHC-Based definitions for each subtype in the molecular classification
A 5 marker panel (ER, PR, HER2, Ki-67, and EGFR) was used to determine each subtype of breast cancer. The definition and number of breast cancer in each subtype for the current study are shown in Table 8.

Statistical analysis
Apart from the descriptive statistics, such as mean of continue variables and percent for categorical variables, the difference between AR positive and AR negative was tested by using two-sided Spearman two-sample test rank for continue variables and Fisher’s exact test was used for categorical variables. The software SAS 9.2 (Cary, NC, USA) was used in the data analysis.

Results
The age of patients ranged from 22 to 94 years old, with a mean age of 51 years. Among the 980 cases, 868 were infiltrating ductal carcinoma (IDC), 52 were infiltrating lobular carcinoma (ILC), 19 were medullary carcinoma, 21 were mucinous carcinoma, and 20 were rare-types of breast carcinomas including squamous cell carcinoma, neuroendocrine carcinoma, etc. The rate of AR expression was 77%, and the rates for ER, PR and HER2 expression were 61%, 60%, 17%, respectively. AR expression was highest in ILC (87%) and lowest in medullary carcinoma (37%) (Table 2); and highest in grade 1 tumors (91%) and lowest in grade 3 tumors (57%) (Table 3).

AR expression was significantly associated with the expression of ER and PR (P < 0.0001), and also inversely related to tumor size (P = 0.0324) and Ki-67 expression (P = 0.0013). There were no significant associations between the expression of AR and HER2.

Table 2. Expression of AR, ER, PR and HER2 in different types of breast carcinomas.

| Type            | Percent of positive expression (%) |   |   |
|-----------------|------------------------------------|---|---|
|                 | AR                                 | ER| PR|
| IDCa (868 cases)| 77 (668 cases)                     | 62 (538 cases) | 59 (512 cases) |
| ILCb (52 cases) | 87 (45 cases)                      | 67 (35 cases) | 71 (37 cases) |
| Medullary (19 cases) | 37 (7 cases)                     | 11 (2 cases) | 11 (2 cases) |
| Mucinous (21 cases) | 88 (18 cases)                     | 76 (16 cases) | 71 (15 cases) |
| Othersc (20 cases) | 60 (12 cases)                      | 60 (12 cases) | 85 (17 cases) |
| Total cases (980)| 77 (755 cases)                     | 61 (598 cases) | 60 (588 cases) |

Notes: aIDC, Infiltrating Ductal Carcinoma; bILC, Infiltrating Lobular Carcinoma; cOthers, squamous cell carcinoma, neuroendocrine tumors, etc.
Table 3. Expression of AR, ER, PR and HER2 in different histologic grades of IDC.

| Type | Percent of positive expression (%) |
|------|-----------------------------------|
|      | AR                            | ER                | PR             |
| IDC (868 cases) | 77 (668 cases) | 62 (538 cases) | 59 (512 cases) |
| *G1 (55 cases) | 91 (50 cases)     | 82 (45 cases)    | 84 (46 cases)  |
| G1-2 (41 cases) | 90 (37 cases)     | 76 (31 cases)    | 71 (29 cases)  |
| G2 (669 cases) | 76 (509 cases)    | 62 (415 cases)   | 59 (395 cases) |
| G2-3 (73 cases) | 77 (56 cases)     | 53 (39 cases)    | 55 (40 cases)  |
| G3 (30 cases)  | 57 (17 cases)      | 30 (9 cases)     | 23 (7 cases)   |

Note: *G, grade.

Table 4. Correlation between AR expression and age, tumor size, L stage, and expression of ER, PR, HER2, EGFR and Ki67.*

|                      | rs     | P value |
|----------------------|--------|---------|
| Age                  | 0.13350| 0.6022  |
| Tumor size           | -0.31765| 0.0324  |
| Nodal metastasis     | -0.04456| 0.1454  |
| ER expression        | 0.54546| <0.0001 |
| PR expression        | 0.32267| <0.0001 |
| HER2 over-expression | -0.03476| 0.7348  |
| EGFR expression      | -0.03090| 0.4782  |
| Ki-67 expression     | -0.31765| 0.0013  |

Discussion

Like ER and PR, AR is also a steroid hormone nuclear protein, but the clinical significance and functional role of AR has not been well defined in breast cancer.24,25 Studies have shown that AR expression is found in about 70% of breast cancers, 26,27 similar to the 77% we found with our Chinese patients. A study from Poland with 488 cases showed the AR expression rate was 43%, but their criterion for its positivity was not mentioned.28 We confirmed that AR is more frequently expressed in our Chinese breast cancer patients than ER and PR and its expression is closely associated with ER and PR. We observed that 65% of ER negative tumors express AR, higher than the 30% rate from other studies.7,9,11,26,27 The higher rates for ER negative tumors (39%) compared to other studies30,31 may also be explained by the higher cut off point used in the rates of AR expression were 84% for ER positive tumors and 65% for ER negative tumors (Table 5). Interestingly, when comparing the expression of AR in ER positive and ER negative tumors, AR expression was significantly associated with PR expression (P < 0.0001) in ER negative tumors (Table 7), but not in ER positive tumors (Tables 6). Similar observations were seen for the mean Ki-67 levels. Other factors including the age of patients, tumor size, nodal metastasis, and HER2 and EGFR expression were not associated with AR expression in either ER positive or ER negative tumors.

Among the 980 cases, the distribution of Luminal A, Luminal B, Luminal HER2, HER2 over-expression, TN and TN EGFR+ subtypes were 27%, 24%, 21%, 12%, 10% and 6%, respectively (Table 8). AR expression was higher in three ER positive subtypes (Luminal A, Luminal B and luminal HER2 subtypes, range: 80%–90%) and lower in three ER negative subtypes (HER2 over-expression, TN, and TN EGFR+ subtypes, range: 52%–66% Table 9). AR expression was significantly different between luminal HER2 and HER2 over-expression subtypes (P < 0.0001), while there was no significant difference between luminal A and B subtypes, luminal B and luminal HER2 subtypes, HER2 and TN subtypes, HER2 and TN EGFR+ subtypes, and TN and TN EGFR+ subtypes (Table 10).

Table 5. Expression of AR in ER positive and ER negative tumors.

|                      | AR positive cases | Totals cases |
|----------------------|------------------|--------------|
| ER positive          | 503 (84%)        | 597          |
| ER negative          | 248 (65%)        | 383          |
| Total                | 751 (77%)        | 980          |

and the ages of patients, lymph node involvement, or expression of HER2 and EGFR (Table 4).

The rates of AR expression were 84% for ER positive tumors and 65% for ER negative tumors (Table 5). Interestingly, when comparing the expression of AR in ER positive and ER negative tumors, AR expression was significantly associated with PR expression (P < 0.0001) in ER negative tumors (Table 7), but not in ER positive tumors (Tables 6). Similar observations were seen for the mean Ki-67 levels. Other factors including the age of patients, tumor size, nodal metastasis, and HER2 and EGFR expression were not associated with AR expression in either ER positive or ER negative tumors.

Among the 980 cases, the distribution of Luminal A, Luminal B, Luminal HER2, HER2 over-expression, TN and TN EGFR+ subtypes were 27%, 24%, 21%, 12%, 10% and 6%, respectively (Table 8). AR expression was higher in three ER positive subtypes (Luminal A, Luminal B and luminal HER2 subtypes, range: 80%–90%) and lower in three ER negative subtypes (HER2 over-expression, TN, and TN EGFR+ subtypes, range: 52%–66% Table 9). AR expression was significantly different between luminal HER2 and HER2 over-expression subtypes (P < 0.0001), while there was no significant difference between luminal A and B subtypes, luminal B and luminal HER2 subtypes, HER2 and TN subtypes, HER2 and TN EGFR+ subtypes, and TN and TN EGFR+ subtypes (Table 10).
AR expression in Chinese breast cancer patients

Another possibility for this difference may due to the specificity of the antibodies used in the current study.\(^{32}\) Nevertheless, we confirmed that a significant portion of ER negative tumors expressed AR in our patient population, which provides this subgroup with a potential therapeutic target.

Comparing the relationship between AR expression and molecular classification, we found that AR expression is higher in ER positive subtypes than in ER negative subtypes, which is comparable with previous reports,\(^{31,33}\) though the definitions for each subtype were not identical. It is very interesting to see the significant difference in AR expression between Luminal HER2 and HER2 over-expression subtype. Both subtypes over-express HER2, but they are different in their expression of ER and/or PR, suggesting the close relation between AR and ER/PR. A recent study from Micello et al.\(^{34}\) reported a 77% AR expression rate in HER2 positive breast carcinomas, comparable with what we observed in this study (66%–86%). Our prior studies with 17 breast cancer cell lines also showed that all 4 ER negative HER2 positive cell lines expressed AR.\(^{35}\) This is especially interesting since an earlier study\(^{36}\) has suggested that in breast cancer, the growth inhibitory effect resulting from AR activation can counterbalance the growth stimulating effect by HER2 over-expression.

We did not observe an age difference between AR positive and AR negative tumors, even when we subdivided the tumors into ER positive and ER negative groups. Hu et al.\(^{37}\) recently reported that in postmenopausal patients, AR expression is associated with a more favorable prognosis among women with ER-positive tumors, but not among patients with ER-negative tumors. In fact, AR expression is associated with increased breast cancer-related mortality in their patients who have triple negative breast cancer. AR expression is associated with more favorable pathologic features including small tumor size \((P = 0.0324)\) and lower Ki-67 expression \((P = 0.0013)\) in current study, similar to previously reported studies.\(^{31}\)

With the high expression rate of AR, especially in ER negative or TN breast cancer, investigations of AR as a therapeutic target have been the subject of extensive research.\(^{14,38}\) Preclinical studies with breast cancer cell lines have shown the inhibitory role of androgen (such as dehydroepiandrosterone) on ER–/PR–/AR+ cells.\(^{13}\) It is thought that if androgen were used to treat ER–/AR+ tumors, its therapeutic effect would be maximized with aromatase inhibitors, since

| Table 6. Clinical-pathological features for AR expression in ER+ tumors (597 cases). |
|---------------------------------|-----------------|-----------------|-----------------|
|                                | AR+ (503)       | AR- (94)        | \(P\) value     |
| Age (mean years)               | 51.08           | 51.15           | 0.8394          |
| Tumor size (mean cm)           | 2.06            | 2.17            | 0.6322          |
| Positive nodal metastasis (253 cases) | 217 (86%) | 36 (14%)        | 0.4267          |
| Positive PR expression (485 cases) | 415 (86%) | 70 (14%)        | 0.0832          |
| HER2 over-expression (182 cases) | 154 (85%) | 28 (15%)        | 0.9035          |
| Positive EGFR expression (303 cases) | 249 (82%) | 54 (18%)        | 0.1777          |
| High Ki-67 expression (>14%) (283 cases) | 233 (82%) | 50 (18%)        | 0.2605          |
| Mean Ki-67 expression level     | 20.04           | 22.73           | 0.3825          |

Table 7. Clinical-pathological features for AR expression in ER– tumors (383 cases).

|---------------------------------|-----------------|-----------------|-----------------|
|                                | AR+ (248)       | AR- (135)       | \(P\) value     |
| Age (mean years)               | 50.12           | 51.23           | 0.3955          |
| Tumor size (mean cm)           | 2.09            | 2.28            | 0.0956          |
| Positive nodal metastasis (163 cases) | 98 (60%) | 65 (40%)        | 0.1062          |
| Positive PR expression (106 cases) | 86 (81%) | 20 (19%)        | <0.0001         |
| HER2 over-expression (145 cases) | 102 (70%) | 43 (30%)        | 0.0786          |
| Positive EGFR expression (221 cases) | 142 (64%) | 79 (56%)        | 0.8293          |
| High Ki-67 expression (>14%) (241 cases) | 150 (62%) | 91 (38%)        | 0.1861          |
| Mean Ki-67 expression          | 26.19           | 33.98           | 0.0307          |
Table 8. The definitions for each molecular subtype.

|_subtype_ | ER  | PR  | Ki67 | HER2 | EGFR | # of cases |
|---------|-----|-----|------|------|------|------------|
| Luminal A (ER+ and/or PR+, Ki67 < 14%, HER2−) 262 cases (27%) | +   | +   | −    | −    | +    | 90         |
| Luminal A | +   | +   | −    | −    | −    | 106        |
| Luminal A | +   | −    | −    | −    | +    | 17         |
| Luminal A | +   | −    | −    | −    | −    | 12         |
| Luminal A | −   | +    | −    | −    | +    | 17         |
| Luminal A | −   | +    | −    | −    | −    | 20         |
| Luminal B (ER+ and/or PR+, Ki67 > 14%, HER2−) 233 cases (24%) | +   | +   | +    | −    | −    | 73         |
| Luminal B | +   | +   | +    | −    | −    | 80         |
| Luminal B | +   | −    | +    | −    | +    | 19         |
| Luminal B | +   | −    | +    | −    | −    | 18         |
| Luminal B | −   | +    | +    | −    | +    | 21         |
| Luminal B | −   | +    | +    | −    | −    | 22         |
| Luminal HER2 (ER+ and/or PR+, HER2+) 208 cases (21%) | +   | +   | +    | −    | +    | 40         |
| Luminal HER2 | +   | +   | −    | −    | +    | 27         |
| Luminal HER2 | +   | −    | +    | −    | +    | 39         |
| Luminal HER2 | +   | −    | −    | −    | +    | 30         |
| Luminal HER2 | +   | −    | +    | −    | +    | 15         |
| Luminal HER2 | +   | +    | −    | −    | +    | 11         |
| Luminal HER2 | +   | −    | −    | −    | +    | 10         |
| Luminal HER2 | −   | +    | +    | −    | −    | 10         |
| Luminal HER2 | −   | +    | −    | +    | −    | 7          |
| Luminal HER2 | −   | −    | +    | −    | +    | 8          |
| Luminal HER2 | −   | −    | −    | −    | +    | 5          |
| Luminal HER2 | −   | +    | −    | −    | +    | 6          |
| HER2 Over-expression (ER−, PR−, HER2+) 119 cases (12%) | −   | −    | −    | +    | +    | 49         |
| HER2 | −   | −    | +    | −    | +    | 28         |
| HER2 | −   | −    | −    | −    | +    | 22         |
| HER2 | −   | −    | −    | −    | +    | 20         |
| Triple Negative (TN), EGFR+ (ER−, PR−, HER2−) 100 cases (10%) | −   | −    | +    | −    | +    | 73         |
| TN, EGFR+ | −   | −    | −    | +    | −    | 27         |
| Triple Negative (TN), EGFR− (ER−, PR−, HER2−) 58 cases (6%) | −   | −    | −    | −    | −    | 33         |
| Triple Negative | −   | −    | −    | −    | −    | 25         |

Table 9. AR expression in different molecular subtypes.

| Molecular subtypes | Total # | AR+ | %   |
|--------------------|---------|-----|-----|
| Luminal A (ER+ and/or PR+, Ki67 < 14%, HER2−) | 262 | 235 | 90% |
| Luminal B (ER+ and/or PR+, Ki67 > 14%, HER2−) | 233 | 186 | 80% |
| Luminal HER2 (ER+ and/or PR+, HER2+) | 208 | 178 | 86% |
| HER2 over-expression (ER−, PR−, HER2+) | 119 | 78  | 66% |
| Triple negative (TN), EGFR+ (ER−, PR−, HER2−) | 100 | 52  | 52% |
| Triple negative (TN), EGFR− (ER−, PR−, HER2−) | 58  | 32  | 55% |
they block the in vivo conversion of androgen to estrogen.\textsuperscript{39,40} For ER+ tumors, androgen can stimulate cell growth;\textsuperscript{41,42} thus, the therapy should inhibit both ER and AR. Further studies on the role of AR in both ER+ and ER− breast cancers are warranted in order to better understand how this receptor might be exploited as a potential target for therapy.

Acknowledgment
The authors wish to thank Ms. Mary Jackson for her excellent clerical support.

Disclosures
Author(s) have provided signed confirmations to the publisher of their compliance with all applicable legal and ethical obligations in respect to declaration of conflicts of interest, funding, authorship and contributorship, and compliance with ethical requirements in respect to treatment of human and animal test subjects. If this article contains identifiable human subject(s) author(s) were required to supply signed patient consent prior to publication. Author(s) have confirmed that the published article is unique and not under consideration nor published by any other publication and that they have consent to reproduce any copyrighted material. The peer reviewers declared no conflicts of interest.

References
1. Ravdin PM, Srininoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. \textit{J Clin Oncol}. 2001;19:980–91.
2. Goldhirch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2009. \textit{Ann Oncol}. 2009;20:1318–29.
3. Colbeigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. \textit{J Clin Oncol}. 1999; 17:2639–48.
4. Lumachi F, Luisetto G, Basso SM, et al. Endocrine therapy of breast cancer. \textit{Curr Med Chem}. 2011;18:513–22.
5. Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity of title of convenience? \textit{Nat Rev Clin Oncol}. 2010;7:683–92.
6. Lachapelle J, Foulkes WD. Triple-negative and basal-like breast cancer: implications for oncologists. \textit{Curr Oncol}. 2011;18:161–4.
7. Monfar F, Okcu M, Tsybykovsky O, et al. Androgen receptors frequently are expressed in breast carcinomas. Potential relevance to new therapeutic strategies. \textit{Cancer}. 2003;98:703–11.
8. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. \textit{Am J Clin Pathol}. 2003;120:725–31.
9. Hanley K, Wang J, Bourne P, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high grade ductal carcinoma of the breast. \textit{Hum Pathol}. 2008;39:386–92.
10. Pristaau G, Petru E, Stacher E, et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations. \textit{Histopathology}. 2010;57:877–84.
11. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. \textit{Cancer}. 2006;109:25–32.
12. Schippingew R, Regtigtn P, Dandachi N, et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. \textit{Virchows Arch}. 2006;449:24–30.
13. Hardin C, Pommer R, Calhoun K, et al. A new hormonal therapy for estrogen receptor-negative breast cancer. \textit{World J Surg}. 2007;31:1041–6.
14. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. \textit{Future Oncol}. 2008;4:15–21.
15. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. \textit{Nature}. 2000;406:747–52.
16. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. \textit{Proc Natl Acad Sci U S A}. 2001;98:10869–74.
17. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. \textit{Proc Natl Acad Sci U S A}. 2003;100:8418–23.
18. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. \textit{Clin Cancer Res}. 2004;10:5367–74.
19. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. \textit{Mod Pathol}. 2006;19:264–71.
20. Cheang MCU, Chia SK, Voduc D, et al. KI67 index, HER2 status, and prognosis of patients with luminal B breast cancer. \textit{J Natl Cancer Inst}. 2009; 101:736–50.
21. Bhargara R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. \textit{Cancer}. 2010;116:1431–9.
22. Bharagara R, Dabbs DJ. Luminal B breast tumors are not HER2 positive. \textit{Breast Cancer Res}. 2008;10:404–5.
23. World Health Organization. Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. \textit{Eds.} Tavassoli FA and Devilee P. Lyon: IARC Press, 2003.
24. Moe RE, Anderson BO. Androgen and androgen receptors: a clinical neglected sector in breast cancer biology. \textit{J Surg Oncol}. 2006;95:437–9.
25. Suzuki T, Miki Y, Takagi K, et al. Androgens in human breast carcinoma. \textit{Med Mol Morphol}. 2010;43:75–81.
26. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. \textit{BMC Cancer}. 2008;8:149.
27. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast Cancer. \textit{Ann Oncol}. 2010;21:488–92.
28. Agrawal AK, Jelen M, Grzebieniak Z, et al. Androgen receptors as a prognostic and predictive factor in breast cancer. \textit{Folia Histochim Cytobiol}. 2008;46:269–76.
29. Reis-Filho JS, Hayes DF, Dowsett M, et al. American Society of clinical Oncology/Collage of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. \textit{J Clin Oncol}. 2010;28:2784–95.

Table 10. P-value of AR expression between subtypes.

| Molecular subtypes | P-values |
|--------------------|----------|
| Luminal A vs. Luminal B | 0.0927 |
| Luminal B vs. Luminal HER2 | 0.1317 |
| Luminal HER2 vs. HER2 Over-expression | <0.0001 |
| HER2 vs. TN | 0.1909 |
| HER2 vs. TN EGFR+ | 0.0531 |
| TN vs. TN EGFR+ | 0.7426 |
30. Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. *Int J Clin Oncol*. 2008;13:431–5.

31. Niemeier LA, Dabb DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. *Mod Pathol*. 2010; 23:205–12.

32. Ibrahim M, Dodson A, Barnett S, et al. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2). *Am J Clin Pathol*. 2008;129:398–9.

33. Collins L, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the nurses’ health study. *Mod Pathol*. advance online publication: doi: 2011;10:1038.

34. Micello D, Marando A, Sahmone N, et al. Androgen receptor is frequently expressed in HER2-positive ER/PR-negative breast cancers. *Virchows Arch*. 2010;457:467–76.

35. Subik K, Lee JF, Baxter L, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. *Breast Cancer (Auckl)*. 2010;4:35–41.

36. Kollara A, Kahn HJ, Marks A, Brown TJ. Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. *Breast Cancer Res Treat*. 2001;67:245–53.

37. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. *Clin Cancer Res*. 2011; 17:1867–74.

38. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. *Cancer J*. 2010;16:62–5.

39. Macedo LF, Guo Z, Tilghman SL, et al. Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole. *Cancer Res*. 2006;66:7775–82.

40. Suzuki T, Miki Y, Akahira J, et al. Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. *Endocr J*. 2008;55:455–63.

41. Calhoun KE, Pommier RF, Muller P, Fletcher WS, Toth-Fejel S. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. *Arch Surg*. 2003;138:879–83.

42. Toth-Fejel S, Cheek J, Calhoun K, Muller P, Pommier RF. Estrogen and androgen receptors as co-mediators of breast cancer cell proliferation. Providing a new therapeutic tool. *Arch Surg*. 2004;139:50–4.

---

Publish with Libertas Academica and every scientist working in your field can read your article

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

Your paper will be:

- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

http://www.la-press.com